ClinicalTrials.gg
RecruitingNCT06946641Updated Jul 31, 2025

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients

A Phase 1 interventional study of QLS12010 and Placebo in Atopic Dermatitis, Hidradenitis Suppurativa (HS) and Rheumatoid Arthritis (RA), sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
129th of 190
102 · median 164
Started
2025
with 33 others
Phase 1
38 of 206
14 open now
Primary completion
2025-12
later than 17 of 81 live
Registered
140th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 129th largest by planned enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 38 in phase 1, reaches primary completion later than 17 of the 81 other live ones, and was the 140th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and participants with atopic dermatitis. This study consists of four parts: Part A is a single ascending dose (SAD) study, once sufficient safety and PK data are obtained from the SAD cohorts, the SMC will determine the dosage of initial cohort in Part B, which consists of three multiple ascending doses (MAD) cohorts of QLS12010 Capsules. Part C is a randomized, open-label, two-cycle, crossover food effect study under fasting and fed (high-fat meal) conditions. Part D is to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and preliminary efficacy of QLS12010 Capsules following multiple oral administrations in adult participants with atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis
  • Hidradenitis Suppurativa (HS)
  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Parts A-C:

  • Males and females aged 18-45 (inclusive),
  • Weight: ≥ 50 kg for males and ≥ 45 kg for females, (BMI): 18.0-30.0 kg/m2 (inclusive),

Inclusion Criteria for Part D:

  • Female or male participants between the ages of 18 to 75 years of age.
  • Chronic AD diagnosed by the criteria of Hannifin and Rajka that has been present for at least 6 Months before the Screening Visit.
  • At screening and baseline: EASI score ≥ 16, vIGA-AD™ score ≥ 3, and BSA affected by AD ≥ 10%;
  • The weekly mean score of PP NRS ≥ 4 prior to the first administration (with assessment results for at least 4 days during the week before the first administration [D-7 to D-1]);
  • As judged by the investigator, within 6 months prior to screening, the patient had an inadequate response to topical medication therapy.

General Exclusion Criteria:

  • Participants with diseases that should be excluded as judged by the investigator at screening, including but not limited to the nervous system, psychiatric system, cardiovascular system, blood and lymphatic system, immune system, respiratory system, digestive system, urinary system, metabolic and skeletal system disorders,
  • The 12-lead at screening shows (QT corrected using Fridericia's formula) > 450 ms. If QTcF is > 450 ms, the 12-lead ECG should be repeated 2 more times (at least 3 min apart), and the mean of the 3 measurements will be used to determine whether the participant meets the inclusion criteria,
  • Participants who smoke more than 5 cigarettes per day on average within 6 months before screening or are currently using e-cigarettes,
  • Participants who consume more than 14 units of alcohol per week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine) within 6 months before screening or have a positive breath alcohol test at screening,
  • Participants who have donated more than 400 mL of blood within 3 months or more than 200 mL of blood within 4 weeks before screening, or plan to donate blood during the study,
  • Participants who have received any strong inhibitor or inducer of within 4 weeks before screening,
  • Participants who have received any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks before the first dose or 5 half-lives (whichever is longer).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Single ascending dose cohorts in healthy participants

    Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of QLS12010 or placebo. The starting dose will be 25 mg of QLS12010 or placebo.

    Drug: QLS12010 · Drug: Placebo

  • Experimental
    Multiple ascending dose cohorts in healthy subjects

    Healthy volunteer subject cohorts randomized 8:2 to receive QLS12010 or placebo QD for 14 continuous days. The starting dose of QLS12010 or placebo is based on upcoming data from SAD part.

    Drug: QLS12010 · Drug: Placebo

  • Experimental
    Food Effect Cohort in healthy subjects

    Part C is a two-cycle, crossover study under fasting and fed (high-fat meal) conditions. In Cycle 1, 12 healthy adult participants will be randomly divided into two groups on D-1, with 6 participants in each group receiving a single oral dose of QLS12010 Capsules under fasting or fed conditions, respectively. After completing washout, they will receive crossover administration for the Cycle 2 study.

    Drug: QLS12010

  • Experimental
    Early Efficacy in patients with AD

    Part D of the study plans to enroll 12 adults with moderate to severe atopic dermatitis (AD). Eligible subjects (after screening) will be sequentially assigned to two dose groups (Dose 1 and Dose 2) in the order of their enrollment. Enrollment of Dose 2 may commence only after Dose 1 has completed enrollment of 6 subjects.

    Drug: QLS12010

Interventions

  • QLS12010 oral capsule(s)

  • DrugPlacebo

    Matching placebo oral capsule(s)

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0

    Time frame: up to approximately 1 month

Secondary outcomes

  1. Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]

    Time frame: up to approximately 1 month

  2. Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)]

    Time frame: up to approximately 14 days

  3. Maximum observed plasma concentration (Cmax)

    Time frame: up to approximately 1 month

  4. Time to maximum observed plasma concentration (Tmax)

    Time frame: up to approximately 1 month

  5. Terminal elimination half-life (t1/2)

    Time frame: up to approximately 1 month

  6. Apparent clearance (CL/F)

    Time frame: up to approximately 1 month

  7. Apparent volume of distribution (Vz/F)

    Time frame: up to approximately 1 month

  8. Mean residence time (MRT)

    Time frame: up to approximately 1 month

  9. Changes and percentage changes from baseline in Eczema Area and Severity Index (EASI) scores

    The minimum EASI score is 0, and the maximum EASI score is 72. A score of 0 indicates clear or no eczema; a greater score indicates more severe disease.

    Time frame: at Weeks 1, 2, 3, 4, 5, and 6

  10. Changes and percentage changes from baseline in Investigator's Global Assessment (IGA) scale

    The IGA5-point scale ranges from 0 (clear) to 4 (severe AD). A decrease in score indicates an improvement in signs and symptoms.

    Time frame: at Weeks 1, 2, 3, 4, 5, and 6

  11. Changes and percentage changes from baseline in weekly mean scores of Peak Pruritus Numerical Rating Scale (PP NRS)

    The PP NRS is a single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: at Weeks 1, 2, 3, 4, 5, and 6

  12. Changes and percentage changes from baseline of body surface area (BSA) affected by lesions

    BSA assessment estimates the area of skin lesions in each part of the body, with one palm unit of the patient taken as 1% of the body surface area.

    Time frame: at Weeks 1, 2, 3, 4, 5, and 6

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 9 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 27, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Apr 2026
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06946641
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
Mar 31, 2025
Primary completion
Dec 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
Jul 31, 2025

Study contacts

Haiyan Li, M.D.
Contact
haiyanli1027@hotmail.com
(+86) 18600489179
Wenhui Wang, M.D.
Contact
wwh0608@126.com
(+86) 15611908751

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS12010

Start the discussion